NCT06547112 2025-08-29
A Pharmacodynamic Study of the Apheresis Product of Multiple Myeloma Patients Undergoing Quad-induction Followed by Motixafortide + G-CSF Mobilization
Washington University School of Medicine
Phase 1 Completed
Clinical Trials
10 trialsNCT02043847 2024-11-13
BMT-03
University of Illinois at Chicago
Phase 1 Completed
NCT02960646 2023-02-16
Engineered Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies
M.D. Anderson Cancer Center
Phase 1 Completed
NCT03018223 2021-09-16
Calcineurin Inhibitor-Free GVHD Prevention Regimen After Related Haplo PBSCT
H. Lee Moffitt Cancer Center and Research Institute
Phase 1 Completed
NCT01248923 2020-09-30
A Study of ARRY-520 and Bortezomib Plus Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma
Array BioPharma
Phase 1 Completed
NCT03506802 2020-07-24
NYSCT MM
Jonsson Comprehensive Cancer Center
Phase 1 Withdrawn
NCT02043860 2019-10-14
BMT-02
University of Illinois at Chicago
Phase 1 Terminated
NCT02220608 2018-01-08
Phase I Study of Bortezomib With G-CSF for Stem Cell Mobilization in Patients With Multiple Myeloma
Washington University School of Medicine
Phase 1 Completed
NCT01074060 2013-02-15
Plerixafor and Filgrastim Following Cyclophosphamide for Stem Cell Mobilization in Patients With Multiple Myeloma
City of Hope Medical Center
Phase 1 Completed
NCT00400556 2006-11-17
ATRA Plus G-CSF for Mobilization of Hematopoietic Stem and Progenitor Cells
Peter MacCallum Cancer Centre, Australia
Phase 1 Completed